Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AHA-PLUS
NCT07393438Phase 2Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Feb 2026
- Primary completion
- Feb 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of acetohydroxamic acid in multidrug-resistant tuberculosis (MDR-TB), sponsored by Shanghai Pulmonary Hospital. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
acetohydroxamic acid
03
Conditions
multidrug-resistant tuberculosis (MDR-TB)
Beyond the preview
Go deeper on NCT07393438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07393438.